Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0K0KR
|
||||
Former ID |
DNC004937
|
||||
Drug Name |
AR-129330
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C25H29BrF3N5O3S
|
||||
Canonical SMILES |
CN(C)C1=NC(=NC2=CC=CC=C21)NCC3CCC(CC3)CNS(=O)(=O)C4=C(C<br />=C(C=C4)Br)OC(F)(F)F.Cl
|
||||
InChI |
1S/C25H29BrF3N5O3S.ClH/c1-34(2)23-19-5-3-4-6-20(19)32-24(33-23)30-14-16-7-9-17(10-8-16)15-31-38(35,36)22-12-11-18(26)13-21(22)37-25(27,28)29;/h3-6,11-13,16-17,31H,7-10,14-15H2,1-2H3,(H,30,32,33);1H
|
||||
InChIKey |
SMEDDEAAKQVMQD-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Melanin-concentrating hormone receptor 1 | Target Info | Inhibitor | [1] | |
Alpha-2A adrenergic receptor | Target Info | Inhibitor | [1] | ||
Neuropeptide Y receptor 5 | Target Info | Inhibitor | [1] | ||
KEGG Pathway | Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway | ||||
Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | |||||
PANTHER Pathway | Alpha adrenergic receptor signaling pathway | ||||
Reactome | Peptide ligand-binding receptors | ||||
G alpha (q) signalling events | |||||
G alpha (i) signalling eventsR-HSA-390696:Adrenoceptors | |||||
Adrenaline signalling through Alpha-2 adrenergic receptor | |||||
Adrenaline,noradrenaline inhibits insulin secretion | |||||
G alpha (i) signalling events | |||||
G alpha (z) signalling events | |||||
Surfactant metabolismR-HSA-375276:Peptide ligand-binding receptors | |||||
WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP58:Monoamine GPCRs | |||||
Platelet Aggregation (Plug Formation) | |||||
Integration of energy metabolism | |||||
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
Peptide GPCRs | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.